DDW Editor Reece Armstrong speaks to Michael Metzger, CEO of Syndax, about its work on developing therapeutics for challenging cancer targets.    RA: What are the unmet needs in relapsed or refractory acute leukaemia. How great is this unmet need in paediatric patients?   MM: Syndax is initially focused on two forms of aggressive, life-threatening acute […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!